Drug Profile
Ifenprodil - Algernon Pharmaceuticals
Alternative Names: NP 120Latest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator Algernon Pharmaceuticals
- Developer Algernon Pharmaceuticals; Dartmouth College
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antipsychotics; Antitussives; Antivirals; Benzyl compounds; Peripheral vasodilators; Phenols; Piperidines; Small molecules; Vascular disorder therapies
- Mechanism of Action Alpha adrenergic receptor antagonists; NMDA receptor antagonists; Sigma-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Cough; Idiopathic pulmonary fibrosis
- Preclinical Acute lung injury; Influenza A virus H5N1 subtype; Neuroendocrine tumours; Pancreatic cancer; Small cell lung cancer
- Research Respiration disorders
- No development reported Crohn's disease; Ulcerative colitis
- Discontinued COVID 2019 infections